Arecor and TRx BioSciences Establish Partnership for Advancing Oral GLP-1 Therapy with Improved Bioavailability
Arecor Therapeutics plc (AIM: AREC), a biopharmaceutical company focused on advancing modern therapies for improved health outcomes, has teamed up with TRx Biosciences Limited, a leader in innovative lipid technology for oral drug delivery. Together, they have announced a research collaboration aimed at formulating an oral glucagon-like peptide-1 (GLP-1) receptor agonist product.
GLP-1 Receptor Agonists: Funds & Challanges
- GLP-1 receptor agonists are crucial for managing type 2 diabetes and obesity.
- The global market for these treatments is projected to reach $80-$100+ billion by 2030.
- However, delivering these drugs orally presents significant challenges due to the digestive system's proteolytic nature, resulting in reduced bioavailability.
- Currently, injection remains the primary delivery method, limiting patient adoption, compliance, and usage.
- Aim for thi collaboration
- The only oral GLP-1 receptor agonist available to patients is Novo Nordisk’s semaglutide (Rybelsus®), which boasts less than 1% oral bioavailability.
- To address this issue, Arecor and TRx Biosciences plan to utilize TRx Biosciences’ LipiCore™ oral delivery technology along with Arecor’s formulation platform, Arestat™.
- This collaboration aims to develop an oral GLP-1 receptor agonist product with improved physicochemical properties to achieve higher oral bioavailability and stability.
Arecor CEO on Challanges
- Sarah Howell, CEO of Arecor, highlighted the ongoing challenges in oral delivery for GLP-1 receptor agonists and expressed optimism in leveraging Arecor's Arestat™ technology alongside TRx Biosciences' expertise to develop an enhanced oral product.
- Dr. Robin Bannister, CEO of TRx Biosciences, emphasized the importance of effective oral peptide delivery and the potential of combining LipiCore™ with Arecor's platform to unlock novel oral uptake channels and protect peptides during gastrointestinal transit.
Novel GLP-1 Receptor Agonist
- The collaboration aims to extend beyond the initial GLP-1 receptor agonist program to develop additional oral peptide products, potentially targeting obesity-related health conditions and other therapeutic areas.
- Success in this endeavor could revolutionize oral peptide therapy, providing patients with more convenient and effective treatment options.
